340B Support By the Numbers

By 340B Matters

2020 was a difficult year for America’s healthcare first responders. But even during the worst health crisis of our lifetime, they never hesitated to put their own lives at risk to save others. With every new case they persevered, even as their workforce was slashed and hospital operating margins plummeted.  

But while these healthcare heroes went the extra mile to care for patients in a time of great need, six drug companies launched a unilateral attack on a program that helps hospitals and clinics stretch scarce resources and ensure access to care. These companies deserve to be called “The Shameful Six.” 

Drugmakers have always had a vendetta against the 340B Drug Discount Program because it requires them to sell some drugs at a lower price to healthcare providers that serve a high percentage of uninsured and underinsured patients. This recent assault from Eli Lilly, AstraZeneca, Sanofi, Novartis, United Therapeutics, and Novo Nordisk is nothing more than a money mongering scheme to rake in excessive profits.

There is widespread bipartisan support for 340B, and lawmakers, hospitals, health associations, and advocacy groups are rallying together to fight back against this seige.

But don’t take our word for it – the numbers speak for themselves. 

Here’s a look at what folks across the nation are doing to stop the Shameful Six’s assault and protect the 340B Drug Discount Program when we need it most: